TrialAnnals of hematology2024

Predictors for improvement in patient-reported outcomes: post hoc analysis of a phase 3 randomized, open-label study of eculizumab and ravulizumab in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria.

Hubert Schrezenmeier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.